首页> 美国卫生研究院文献>Joints >Survival Analysis after Core Decompression in Association with Platelet-Rich Plasma Mesenchymal Stem Cells and Synthetic Bone Graft in Patients with Osteonecrosis of the Femoral Head
【2h】

Survival Analysis after Core Decompression in Association with Platelet-Rich Plasma Mesenchymal Stem Cells and Synthetic Bone Graft in Patients with Osteonecrosis of the Femoral Head

机译:伴有丰富血小板的血浆间充质干细胞和合成骨移植物在股骨头坏死患者中进行核心减压后的生存分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Purpose  The aim of this study was to report the rate of survivorship in patients with osteonecrosis of the femoral head treated with core decompression in association with mesenchymal stem cells (MSCs) implantation, platelet-rich plasma (PRP) injection, and synthetic bone graft. >Methods  We evaluated 24 hips in 16 patients, according to Ficat classification, treated by core decompression, injection of PRP and MSCs, and backfilling of the core tract with synthetic bone graft. Survivorship was estimated using Kaplan–Meier curves. >Results  The survivorship of core decompression in association with the procedure is 50% at 75 months of follow-up. The survival rate was 80% for patients in early stage and 28.6% for patients in advanced stage at 75 months. When we compared Kaplan–Meier survival curves of patients in stage III + IV and patients in stage I + II, we noticed that the survival functions are statistically different ( p  < 0.05, log-rank test), particularly in stage I + II where we had a greater surviving core decompression, in comparison to patients in stage III + IV. >Conclusion  This technique is safe and good preliminary results were obtained in patients with early stages of the disease with no reported complications. >Level of Evidence  Level IV, therapeutic case series.
机译:>目的本研究的目的是报告经核心减压联合间充质干细胞(MSCs)植入,富血小板血浆(PRP)治疗的股骨头坏死患者的存活率注射和合成骨移植。 >方法我们根据Ficat分类法,对16例患者的24髋进行了评估,这些患者接受了心脏减压,注射PRP和MSC以及用合成骨移植物回填核心区域的治疗。使用Kaplan-Meier曲线估算生存率。 >结果在随访75个月时,与手术相关的核心减压的生存率为50%。早期患者在75个月时的生存率为80%,晚期患者为28.6%。当我们比较III + IV期患者和I + II期患者的Kaplan–Meier生存曲线时,我们注意到其生存功能有统计学差异(p <0.05,对数秩检验),特别是在I + II期。与III + IV期患者相比,我们的核心减压生存率更高。 >结论这种技术是安全的,并且在疾病早期阶段并没有并发症的患者中获得了良好的初步结果。 >证据级别:IVIV级,治疗病例系列。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号